Stocks and Investing Stocks and Investing
Tue, September 11, 2012
Mon, September 10, 2012

ARCA Biopharma Inc (NASDAQ:ABIO), Up By 5.71% ($0.02) From $0.350 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bu


Published on 2012-09-10 07:41:49 - WOPRAI
  Print publication without navigation


September 10, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Friday, September 7th 2012 stating that ARCA Biopharma Inc (NASDAQ:ABIO) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=abio&id=308001

At the time this story was written, ARCA Biopharma Inc (NASDAQ:ABIO) is Up By $0.02 (5.71%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

ARCA Biopharma Inc (NASDAQ:ABIO) - ARCA biopharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of genetically-targeted therapies for heart failure and other cardiovascular diseases in the United States. The companys lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator for the treatment of chronic heart failure and other indications. Its development pipeline includes rNAPc2, a long-acting recombinant protein anticoagulant with a mechanism of action involving inhibition of tissue factor; and NU172, a short-acting anticoagulant, under collaboration agreement with Archemix Corporation, used during medical or surgical procedures. ARCA biopharma has a collaboration agreement with Laboratory Corporation of America to develop the genetic test for Gencaro. The company is headquartered in Broomfield, Colorado.There is a failure to deliver in shares of ABIO

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources